Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non–small-cell Lung Cancer: Study Protocol for an …
J Ma, G Pi, J Bi, Y Li, H He, Y Li, D Hu, V Verma… - Clinical Lung Cancer, 2021 - Elsevier
Brain radiotherapy (BR) is a well-recognized approach for multiple brain metastases (BMs)
from non–small-cell lung cancer (NSCLC). However, the prognosis for these patients …
from non–small-cell lung cancer (NSCLC). However, the prognosis for these patients …
[HTML][HTML] Efficacy and safety of apatinib combined with whole-brain radiation therapy with a simultaneous integrated boost for brain metastases from non-small cell lung …
J Ma, J Bi, X Tuo, G Pi, Y Li, Y Li, F Zeng… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Background Brain metastases (BMs) develop in 20–65% of non-small cell lung cancer
(NSCLC) patients and are associated with a poor prognosis. Apatinib, a tyrosine kinase …
(NSCLC) patients and are associated with a poor prognosis. Apatinib, a tyrosine kinase …
Clinical response to apatinib combined with brain radiotherapy in EGFR wild-type and ALK-negative lung adenocarcinoma with multiple brain metastases
X Ying, H Liu, M Wang, M Peng, P Ruan… - Frontiers in …, 2020 - frontiersin.org
Background: Brain radiotherapy is the standard treatment option for multiple brain
metastases (BMs) from non-small cell lung cancer (NSCLC), especially in the absence of a …
metastases (BMs) from non-small cell lung cancer (NSCLC), especially in the absence of a …
Efficacy of apatinib+radiotherapy vs radiotherapy alone in patients with advanced multiline therapy failure for non small cell lung cancer with brain metastasis
H Pan, X Zhou, L Shen, Y Li, W Dong… - The British Journal of …, 2023 - academic.oup.com
Objective: Lung cancer is the leading cause of cancer-associated mortality worldwide.
Central nervous system (CNS) metastasis is a prevalent and serious complication. The most …
Central nervous system (CNS) metastasis is a prevalent and serious complication. The most …
Whole-brain radiotherapy combined with anlotinib for multiple brain metastases from non-small cell lung cancer without targetable driver mutation: A single-arm …
J Liu, J Xu, W Ye, W Zhong, X Zhang… - Clinical Medicine …, 2022 - journals.sagepub.com
Background: Existing evidence demonstrates that radiotherapy and antiangiogenic drugs
have synergistic antitumour effects and may be a promising treatment option for patients with …
have synergistic antitumour effects and may be a promising treatment option for patients with …
[HTML][HTML] Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases
J Xu, X Liu, S Yang, Y Shi - Oncology Research, 2020 - ncbi.nlm.nih.gov
Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in
China, exerts antiangiogenic and antineoplastic function through selectively binding and …
China, exerts antiangiogenic and antineoplastic function through selectively binding and …
[HTML][HTML] Apatinib plus docetaxel or pemetrexed shows promising activities against non-small cell lung cancer with brain metastasis: a retrospective analysis
J Tang, H Jiang, Z Xiang, X Zhu, R Xie… - Journal of Thoracic …, 2024 - ncbi.nlm.nih.gov
Background So far, the treatment options for most advanced non-small cell lung cancer
(NSCLC) with brain metastasis have been limited. Apatinib, an oral tyrosine kinase inhibitor …
(NSCLC) with brain metastasis have been limited. Apatinib, an oral tyrosine kinase inhibitor …
Continuous low-dose apatinib combined with WBRT significantly reduces peritumoral edema and enhances the efficacy of symptomatic multiple brain metastases in …
Y Ren, SB Wang, L Zhou, SQ Liu… - … in Cancer Research …, 2021 - journals.sagepub.com
Background: Symptomatic multiple brain metastases with peritumoral brain edema (PTBE)
occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or …
occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or …
A phase II study of anlotinib plus whole brain radiation therapy for patients with NSCLC with multiple brain metastases
D Gu, H Yu, N Ding, J Xu, P Qian, J Zhu… - Annals of …, 2024 - Taylor & Francis
Background Whole brain radiotherapy (WBRT) is the mainstay of treatment for patients with
non-small cell lung cancer (NSCLC) with multiple brain metastases (BMs); however, the …
non-small cell lung cancer (NSCLC) with multiple brain metastases (BMs); however, the …
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non …
I Monnet, A Vergnenègre, G Robinet… - Therapeutic …, 2021 - journals.sagepub.com
Background: The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients
with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases …
with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases …
相关搜索
- brain metastases radiation therapy
- concurrent apatinib brain radiotherapy
- brain metastases driver mutation
- concurrent apatinib lung cancer
- lung cancer brain radiotherapy
- brain metastases safety of apatinib
- clinical response brain radiotherapy
- brain metastases peritumoral edema
- brain metastases lung adenocarcinoma
- brain metastasis radiotherapy alone
- radiation therapy safety of apatinib
- brain metastases veliparib in combination
- combination therapy apatinib monotherapy
- brain metastases concurrent apatinib
- brain metastases lung cancer
- brain metastases apatinib monotherapy